Figure 1.
Clinical Outcomes. (A) Swimmer plot for patients who received CAR19-22 and NKTR-255; 3 patients received NKTR-255 dose-level 1 (1.5 μg/kg, green), 4 patients received dose-level 2 (3.0 μg/kg, orange), and 2 patients received dose-level 3 (6.0 μg/kg, blue). Circles represent doses of NKTR-255, squares represent allogeneic stem cell transplant, and X’s represent relapse. (B) PFS for patients who received NKTR-255 (n = 9) with events as death or relapse and without censoring for allogeneic HCT. (C) PFS considering allogeneic HCT as censoring event.

Clinical Outcomes. (A) Swimmer plot for patients who received CAR19-22 and NKTR-255; 3 patients received NKTR-255 dose-level 1 (1.5 μg/kg, green), 4 patients received dose-level 2 (3.0 μg/kg, orange), and 2 patients received dose-level 3 (6.0 μg/kg, blue). Circles represent doses of NKTR-255, squares represent allogeneic stem cell transplant, and X’s represent relapse. (B) PFS for patients who received NKTR-255 (n = 9) with events as death or relapse and without censoring for allogeneic HCT. (C) PFS considering allogeneic HCT as censoring event.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal